Copyright © Inderes 2011 - present. All rights reserved.

Medicover

202.50 SEK

-1.70 %

Less than 1K followers

MCOV B

NASDAQ Stockholm

Health Care Providers

Health Care

-1.70 %
-8.16 %
-8.16 %
-21.97 %
-26.63 %
-1.22 %
+10.90 %
+28.16 %
+209.16 %

Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.

Read more
Market cap
31.09B SEK
Turnover
16.7M SEK
Revenue
23.99B
EBIT %
3.36 %
P/E
157.64
Dividend yield-%
0.85 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10/2
2026

Annual report '25

29/4
2026

General meeting '26

29/4
2026

Interim report Q1'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Medicover: Expect to see new targets - ABG

* Q4'25 numbers due on 10 February at 07:45 CET * Expect new targets on the reporting day, more info on 11 Feb * Fair value range down to SEK 200-280 (220-300) Q4'25 expectations The end of 2025 should be characterised by a similar trend to Q3 for Medicover...

Medicover
Third party research

Medicover: Execution remains solid - ABG

* Operational leverage supports beat on adj. EBITDA* Adj. EBITDA revised by +1-0% for '25e-'27e* Unchanged outlook and fair value range of SEK 220-300Continues to show strengthQ3 proved marginally weaker than expected on sales, but operational leverage...

Medicover
Third party research

Medicover: Margins expand, despite slower growth - ABG

* +5%/+3% adj. EBITDA vs ABGSCe/Infront cons in Q3* Cons estimates likely up 1-2% on adj. EBITDA '25e* Somewhat lower sales but profitability continues to improveQ3 resultsMedicover reported a solid Q3 with a miss on sales but a beat on adj. EBITDA (...

Medicover
Third party research

Medicover: Strong and stable core, minor adjustments - ABG

* Q3'25 numbers due on 5 November at 07:45 CET* Adj. EBITDA down 1% for '25e-'27e* Fair value range unchanged at SEK 220-300 Q3'25 expectations For Q3, we expect Medicover to continue to deliver strong growth in its core regions and drive margin expansion...

Medicover
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.